Cargando…

Systemic sclerosis in the time of COVID-19

The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related to the chronic nature of their disease, the involvement of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann-Vold, Anna-Maria, Distler, Oliver, Bruni, Cosimo, Denton, Christopher P, de Vries-Bouwstra, Jeska, Matucci Cerinic, Marco, Vonk, Madelon C, Gabrielli, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302939/
https://www.ncbi.nlm.nih.gov/pubmed/35891634
http://dx.doi.org/10.1016/S2665-9913(22)00130-8
_version_ 1784751740711600128
author Hoffmann-Vold, Anna-Maria
Distler, Oliver
Bruni, Cosimo
Denton, Christopher P
de Vries-Bouwstra, Jeska
Matucci Cerinic, Marco
Vonk, Madelon C
Gabrielli, Armando
author_facet Hoffmann-Vold, Anna-Maria
Distler, Oliver
Bruni, Cosimo
Denton, Christopher P
de Vries-Bouwstra, Jeska
Matucci Cerinic, Marco
Vonk, Madelon C
Gabrielli, Armando
author_sort Hoffmann-Vold, Anna-Maria
collection PubMed
description The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related to the chronic nature of their disease, the involvement of multiple organs, and the use of immunosuppressive treatments. Data from registries and single centre cohorts indicate that the risk of contracting SARS-CoV-2 does not seem to increase substantially in people with systemic sclerosis; conversely, severe COVID-19 outcomes are seen more frequently in these patients than in the general population. Vaccination against SARS-CoV-2 is therefore highly recommended for patients with systemic sclerosis; however, no specific recommendations are available regarding the different vaccine platforms. Both patients and physicians should be aware that the effectiveness of vaccines might be reduced in patients taking immunosuppressive therapy, because antibody responses might be blunted, specifically in patients treated with rituximab and mycophenolate mofetil.
format Online
Article
Text
id pubmed-9302939
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-93029392022-07-22 Systemic sclerosis in the time of COVID-19 Hoffmann-Vold, Anna-Maria Distler, Oliver Bruni, Cosimo Denton, Christopher P de Vries-Bouwstra, Jeska Matucci Cerinic, Marco Vonk, Madelon C Gabrielli, Armando Lancet Rheumatol Review The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related to the chronic nature of their disease, the involvement of multiple organs, and the use of immunosuppressive treatments. Data from registries and single centre cohorts indicate that the risk of contracting SARS-CoV-2 does not seem to increase substantially in people with systemic sclerosis; conversely, severe COVID-19 outcomes are seen more frequently in these patients than in the general population. Vaccination against SARS-CoV-2 is therefore highly recommended for patients with systemic sclerosis; however, no specific recommendations are available regarding the different vaccine platforms. Both patients and physicians should be aware that the effectiveness of vaccines might be reduced in patients taking immunosuppressive therapy, because antibody responses might be blunted, specifically in patients treated with rituximab and mycophenolate mofetil. Published by Elsevier Ltd. 2022-08 2022-07-21 /pmc/articles/PMC9302939/ /pubmed/35891634 http://dx.doi.org/10.1016/S2665-9913(22)00130-8 Text en Crown Copyright © 2022 Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Hoffmann-Vold, Anna-Maria
Distler, Oliver
Bruni, Cosimo
Denton, Christopher P
de Vries-Bouwstra, Jeska
Matucci Cerinic, Marco
Vonk, Madelon C
Gabrielli, Armando
Systemic sclerosis in the time of COVID-19
title Systemic sclerosis in the time of COVID-19
title_full Systemic sclerosis in the time of COVID-19
title_fullStr Systemic sclerosis in the time of COVID-19
title_full_unstemmed Systemic sclerosis in the time of COVID-19
title_short Systemic sclerosis in the time of COVID-19
title_sort systemic sclerosis in the time of covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302939/
https://www.ncbi.nlm.nih.gov/pubmed/35891634
http://dx.doi.org/10.1016/S2665-9913(22)00130-8
work_keys_str_mv AT hoffmannvoldannamaria systemicsclerosisinthetimeofcovid19
AT distleroliver systemicsclerosisinthetimeofcovid19
AT brunicosimo systemicsclerosisinthetimeofcovid19
AT dentonchristopherp systemicsclerosisinthetimeofcovid19
AT devriesbouwstrajeska systemicsclerosisinthetimeofcovid19
AT matuccicerinicmarco systemicsclerosisinthetimeofcovid19
AT vonkmadelonc systemicsclerosisinthetimeofcovid19
AT gabrielliarmando systemicsclerosisinthetimeofcovid19